Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Blood-based biomarkers for Alzheimer's disease : towards clinical implementation

Teunissen, Charlotte E. ; Verberk, Inge M.W. ; Thijssen, Elisabeth H. ; Vermunt, Lisa ; Hansson, Oskar LU orcid ; Zetterberg, Henrik LU ; van der Flier, Wiesje M. ; Mielke, Michelle M. and del Campo, Marta (2022) In The Lancet Neurology 21(1). p.66-77
Abstract

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question... (More)

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet Neurology
volume
21
issue
1
pages
12 pages
publisher
Lancet Publishing Group
external identifiers
  • pmid:34838239
  • scopus:85121457724
ISSN
1474-4422
DOI
10.1016/S1474-4422(21)00361-6
language
English
LU publication?
yes
id
41cdfe86-5c93-43df-8d5f-dfa465edd204
date added to LUP
2022-01-25 15:51:21
date last changed
2025-03-11 05:54:34
@article{41cdfe86-5c93-43df-8d5f-dfa465edd204,
  abstract     = {{<p>For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.</p>}},
  author       = {{Teunissen, Charlotte E. and Verberk, Inge M.W. and Thijssen, Elisabeth H. and Vermunt, Lisa and Hansson, Oskar and Zetterberg, Henrik and van der Flier, Wiesje M. and Mielke, Michelle M. and del Campo, Marta}},
  issn         = {{1474-4422}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{66--77}},
  publisher    = {{Lancet Publishing Group}},
  series       = {{The Lancet Neurology}},
  title        = {{Blood-based biomarkers for Alzheimer's disease : towards clinical implementation}},
  url          = {{http://dx.doi.org/10.1016/S1474-4422(21)00361-6}},
  doi          = {{10.1016/S1474-4422(21)00361-6}},
  volume       = {{21}},
  year         = {{2022}},
}